Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 26Triple Negative Breast Neoplasms 13Prostatic Neoplasms 12Ovarian Neoplasms 12Neoplasms 10Neoplasm Metastasis 8Fallopian Tube Neoplasms 6Leukemia, Myeloid, Acute 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Carcinoma, Renal Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2mCRPC 1Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Thrombocythemia, Essential 1Solid Tumor 1Sarcoma 1

Interventions

enzalutamide 7Prednisone 7cabazitaxel 6Radiosurgery 6Docetaxel 5Androgen Antagonists 4Abiraterone Acetate 4XRP6258 2Standard of Care 2talazoparib 1sipuleucel-T 1rucaparib 1pembrolizumab 1olaparib 1gallium 68 PSMA-11 1fludrocortisone acetate 1darolutamide 1apalutamide 1Zuclomiphene 1Radiotherapy, Image-Guided 1Radiotherapy 1Prednisolone 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Midazolam 1Lutetium-177 1Lutetium 1Lenograstim 1LY3023414 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostate Cancer Metastatic × talazoparib × Clear all
NCT04824937 2021-04-01

Telaglenastat + Talazoparib In Prostate Cancer

Massachusetts General Hospital

Phase 2 Unknown
30 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡